1. Volume 64, Issue 3, Pages 493-501 (September 2013)
Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia in Real-life Practice in France: A Comprehensive Population Study 
Bertrand Lukacs, Jean-Nicolas Cornu, Mounir Aout, Natacha Tessier, Christophe Hodée, François Haab, Olivier Cussenot, Yvon Merlière, Véronique Moysan, Eric Vicaut 
European Urology 
Volume 64, Issue 3, Pages (September 2013)
DOI: /j.eururo
Copyright © 2013 European Association of Urology Terms and Conditions

2. Fig. 1
Yearly prevalence of medical prescriptions and surgeries related to benign prostatic hyperplasia management, stratified by age groups (5-yr intervals).
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

3. Fig. 2
Adjusted rates (a) of medical treatment in French regions (mean yearly number of prescriptions per men >50 yr of age, 2004–2008) and (b) of surgical treatment in French regions (mean yearly number of surgeries per men >50 yr of age, 2004–2008).
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

4. Fig. 3
Treatment modalities during the study period (whole study population). Retreatment is defined by new lower urinary tract symptoms/benign prostatic obstruction–related treatments the year after treatment was interrupted (eg, patient treated in 2005, not in 2006, and again in 2007).
aNumber of patients treated medically by α1-blockers and/or 5α-reductase inhibitors and/or phytotherapy.
bNumber of patients treated surgically. Patients who underwent recurrent surgery in two different years are included in these figures.
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

5. Fig. 4
Proportion of increase in prescriptions of the three major classes of benign prostatic hyperplasia–related drugs over the study period, stratified by prescriber type. Amount prescribed in 2004 is the reference value. GP=general practitioner; URO=urologist.
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

6. Fig. 5
Evolution of duration of hospital stay for each surgical approach during the study period. Box plots represent the median and interquartile values (Q1, Q3) of duration of hospital stay for each surgical approach over the study period (transurethral resection of the prostate [TURP], transurethral incision of the prostate [TIUP], open prostatectomy [OP], hyperthermia by transurethral microwave therapy [TUMT], and transurethral needle ablation of the prostate [TUNA]. Mean values are shown by square color markers. No data were suitable for analysis for TUNA before 2007 and for TUMT after 2007.
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

7. Fig. 6
Survival without retreatment for benign prostatic obstruction. BPH=benign prostatic hyperplasia; OP=open prostatectomy; TIUP=transurethral incision of the prostate; TUMT=hyperthermia by transurethral microwave therapy; TUNA=transurethral needle ablation of the prostate; TURP=transurethral resection of the prostate.
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

8. Fig. 7
Cumulative incidence of medical treatment prescribed after surgical treatment. To avoid overestimating drug prescriptions after surgery, the first three postoperative months were not considered. The share of each treatment (α-blockers, 5α-reductase inhibitors, plants, or combination) was based on annual prescription volumes in patients with a history of surgical treatment of benign prostatic hyperplasia (Supplementary Table 3). Cumulative incidence is described monthly for the first year and yearly after 12 mo.
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions